Paysign Q3 revenue beats on patient affordability programs
PAYS•Paysign’s third-quarter 2026 revenue rose 43% to $30.8 million, above the $29.02 million analyst estimate, while gross margin expanded to 64.7%. The company raised its full-year guidance for gross margin, net income, GAAP EPS and adjusted EBITDA and expects 2026 revenue of $114 million to $117 million.
1. Revenue and margins rise
Paysign reported third-quarter 2026 revenue of $30.8 million, up 43% and above the $29.02 million analyst estimate. Net income was $6.74 million, and gross margin was 64.7%, which the company attributed to growth in patient affordability programs and a higher share of pharmaceutical revenue.
2. Full-year outlook raised
Paysign raised its 2026 guidance for gross margin, net income, GAAP EPS and adjusted EBITDA. It expects revenue of $114 million to $117 million and to exit the year with 190 to 195 patient affordability programs and 445 to 450 plasma centers. Higher average revenue per plasma center offset the impact of a declining center count.
